BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk ...
Add Yahoo as a preferred source to see more of our stories on Google. The trial aims to assess biological and clinical activity of TTX-MC138 in patients with MRD. Credit: Pickadook / Shutterstock.com.
(MENAFN- Investor Brand Network) TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug (“IND”) application amendment to the U.S. Food and Drug Administration ...
A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational new drug (IND) application amendment seeking approval from the US Food and ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
without a vote A/76/617/Add.1 Financial reports and audited financial statements, and reports of the Board of Auditors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results